170 related articles for article (PubMed ID: 35467016)
1. Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors.
Karas S; Mathijssen RHJ; van Schaik RHN; Forrest A; Wiltshire T; Innocenti F; Bies RR
Clin Pharmacol Ther; 2022 Aug; 112(2):316-326. PubMed ID: 35467016
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.
Karas S; Mathijssen RHJ; van Schaik RHN; Forrest A; Wiltshire T; Bies RR; Innocenti F
Clin Pharmacol Ther; 2024 May; 115(5):1162-1174. PubMed ID: 38344867
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
5. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.
Yamada Y; Fujii H; Ohata K; Kato-Hayashi H; Watanabe D; Ishihara T; Uemura S; Iwashita T; Imai H; Matsuhashi N; Takahashi T; Sugiyama T; Shimizu M; Yoshida K; Suzuki A
Med Oncol; 2019 Jun; 36(7):63. PubMed ID: 31161433
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
8. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
González-Sales M; Valenzuela B; Pérez-Ruixo C; Fernández Teruel C; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Nov; 51(11):751-64. PubMed ID: 23055348
[TBL] [Abstract][Full Text] [Related]
12. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.
van Hasselt JG; Gupta A; Hussein Z; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2013 Sep; 76(3):412-24. PubMed ID: 23601153
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
17. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Karas S; Etheridge AS; Nickerson DA; Cox NJ; Mohlke KL; Cecchin E; Toffoli G; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
Br J Cancer; 2022 Mar; 126(4):640-651. PubMed ID: 34703007
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
[TBL] [Abstract][Full Text] [Related]
19. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]